NCT05715320View on ClinicalTrials.gov

Study of CM310 Injection in Subjects With Moderate-to-Severe Atopic Dermatitis

PHASE2CompletedINTERVENTIONAL
Enrollment

160

Participants

Timeline

Start Date

March 10, 2023

Primary Completion Date

July 18, 2024

Study Completion Date

July 18, 2024

Conditions
Atopic Dermatitis
Interventions
BIOLOGICAL

CM310

IL-4Rα monoclonal antibody

Trial Locations (1)

Unknown

Hangzhou First People's Hospital, Hangzhou

Sponsors
All Listed Sponsors
lead

Keymed Biosciences Co.Ltd

INDUSTRY

NCT05715320 - Study of CM310 Injection in Subjects With Moderate-to-Severe Atopic Dermatitis | Biotech Hunter | Biotech Hunter